Staar Surgical (NASDAQ:STAA) insider have most recently took part in a trading activity. On Jun 29, 2016 Broadwood Partners Lp, 10% Owner bought 14,144 shares having total worth of $74,115 at the price of $5.24 per share, following the transaction a total of 21,736,258 shares owned by Broadwood Partners Lp. Before this latest buy, Broadwood Partners Lp purchased STAA at 15 other times during the past twelve months, for a total investment of $190.6M at an average of $6.45 per share.
The stock has experienced a total of 4 insider trades in the past three months. These trades include 1 sell activities and 3 buy trades. Furthermore, over the past 12 months , the stock was traded 21 times by insiders. In 1 of these trades, the insider was a seller while an employee of the company was the buyer in 20 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Staar Surgical (NASDAQ:STAA) traded up 0.76% on Jun 29, 2016, hitting $5.3. 83,300 shares of the company’s stock traded hands. Staar Surgical has a 52 week low of $5.12 and a 52 week high of $10.63. The company’s market cap is $213 million.
Staar Surgical (NASDAQ:STAA) last announced its earnings results on May 11, 2016. The company reported -0.01 earnings per share (EPS) for the quarter, higher than the consensus estimate of -0.17 by $0.16. The company had revenue of $19 million for the quarter, compared to the consensus estimate of $20 million. During the same quarter in the previous year, the company posted -0.03 earnings per share.
|earnings per share||-0.01||0.01||0.00||0.00||-0.03||-0.03||0.00||0.01||0.04||0.02|
STAAR Surgical was incorporated in the state of California in 1982. It was reincorporated in Delaware in 1986. The Company designs, develops, manufactures and sells implantable lenses for the eye. The Company is a maker of lenses used worldwide in corrective surgery, and it also make lenses for use in surgery that treats cataracts. All of the lenses it make are foldable, which permits the surgeon to insert them through a small incision during minimally invasive surgery. The Company maintains manufacturing and administrative facilities in the United States, Switzerland and Japan. The Company operates its global administrative headquarters and a manufacturing facility in Monrovia, California. The Monrovia manufacturing facility principally makes Collamer and silicone IOLs and injector systems for IOLs and ICLs. STAAR also currently manufactures the raw material for Collamer lenses (both IOLs and ICLs) and the AquaFlow Device (for the treatment of glaucoma) in a facility in Aliso Viejo, California. It operates an administrative, manufacturing and distribution facility in Nidau, Switzerland under its wholly owned subsidiary, STAAR Surgical AG. The Nidau manufacturing facility makes all of STAAR’s Visian ICL products and also manufactures the AquaFlow Device. After consolidating manufacturing in Monrovia, California, STAAR plans to continue to maintain an administrative and distribution facility in Switzerland. It operates administrative, manufacturing and distribution facilities in Japan under its wholly owned subsidiary, STAAR Japan Inc. STAAR Japan’s administrative facility is located in Shin-Urayasu and its manufacturing and distribution facility is located in Ichikawa City. STAAR currently assembles all of its preloaded IOL injectors at the Ichikawa City facility. After consolidating manufacturing in Monrovia, California, the Company plans to continue to maintain administrative and distribution facilities in Japan. The Company is subject to periodic inspection by the FDA for compliance with the FDA’s quality system regulations and requirements, such as restrictions on advertising and promotion.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018